BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20697802)

  • 1. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
    Morrow PK; Divers S; Provencher L; Luoh SW; Petrella TM; Giurescu M; Schmelter T; Wang Y; Hortobagyi GN; Vahdat LT
    Breast Cancer Res Treat; 2010 Oct; 123(3):837-42. PubMed ID: 20697802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
    Heigener DF; von Pawel J; Eschbach C; Brune A; Schmittel A; Schmelter T; Reck M; Fischer JR
    Lung Cancer; 2013 Jun; 80(3):319-25. PubMed ID: 23522488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
    Rustin G; Reed N; Jayson GC; Ledermann JA; Adams M; Perren T; Poole C; Lind M; Persic M; Essapen S; Gore M; Calvert H; Stredder C; Wagner A; Giurescu M; Kaye S
    Ann Oncol; 2011 Nov; 22(11):2411-2416. PubMed ID: 21372124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
    Galmarini CM
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases.
    Freedman RA; Bullitt E; Sun L; Gelman R; Harris G; Ligibel JA; Krop IE; Partridge AH; Eisenberg E; Winer EP; Lin NU
    Clin Breast Cancer; 2011 Dec; 11(6):376-83. PubMed ID: 21697017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
    Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
    J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.
    Gauler TC; Christoph DC; Fischer J; Frickhofen N; Huber R; Gonschorek C; Roth K; Giurescu M; Eberhardt WE
    Eur J Cancer; 2013 Jul; 49(11):2461-8. PubMed ID: 23692812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.
    McMeekin S; Patel R; Verschraegen C; Celano P; Burke J; Plaxe S; Ghatage P; Giurescu M; Stredder C; Wang Y; Schmelter T
    Br J Cancer; 2012 Jan; 106(1):70-6. PubMed ID: 22108514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
    Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
    J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial.
    Arnold D; Voigt W; Kiewe P; Behrmann C; Lindemann S; Reif S; Wiesinger H; Giurescu M; Thiel E; Schmoll HJ
    Br J Cancer; 2009 Oct; 101(8):1241-7. PubMed ID: 19773753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
    Stupp R; Tosoni A; Bromberg JEC; Hau P; Campone M; Gijtenbeek J; Frenay M; Breimer L; Wiesinger H; Allgeier A; van den Bent MJ; Bogdahn U; van der Graaf W; Yun HJ; Gorlia T; Lacombe D; Brandes AA
    Ann Oncol; 2011 Sep; 22(9):2144-2149. PubMed ID: 21321091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.